Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT03668327
Recruiting Observational

Preterm Birth Cohort Study in Guangzhou

NCT03668327 · tracked via the Priya Life Science China tracker
Sponsor
Guangzhou Women and Children's Medical Center
Phase
Observational
Started
2012-02-01
Last updated
2024-02-26

Condition(s) studied

Preterm BirthNeurodevelopmentImmune DevelopmentHost and Microbiome

Study summary

The Preterm Birth Cohort Study in Guangzhou (PBCSG) aims to explore the impact of genetic and environmental factors including life styles on preterm birth, to examine the interaction effect between these factors, and to follow up the short-term and long-term outcomes of preterm childrens.

Eligibility

Sex
ALL
Min age
—
Max age
18 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Born before 37 weeks of gestation 2. Born in Guangzhou Women and Children's Medical Center 3. Intended to remain in Guangzhou for more than 3 years Exclusion Criteria: 1. Multiple birth 2. Stillbirth 3. With major congenital abnormalities

Primary outcome measure(s)

  • Neurodevelopment at early childhood — At age of 1 year
    Assessed by using the Gesell Developmental Schedules, which include adaptive, gross motor, fine motor, language, and social function domains. Higher score in each domain is considered a better outcome, while no more than 85 is defined as suspected development retardation

Trial sites (1)

FacilityCityRegionStatus
Guangzhou Women and Children's Medical Center, China Guangzhou China Recruiting

More Guangzhou Women and Children's Medical Center trials in China

The Born in Guangzhou Cohort Study (BIGCS) Recruiting
Diagnosis and Management of Intrauterine Growth Restriction and Congenital Anomalies Recruiting
CD19/CD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children. Recruiting
Non-Helium Magnetoencephalography in Pediatric Refractory Epilepsy Recruiting
Offspring Born to Mothers With Polycystic Ovary Syndrome in Guangzhou Cohort Study Recruiting

Other trials for the same condition

The Born in Guangzhou Cohort Study (BIGCS) Recruiting
Prolonged Progesterone to Prevent Preterm Birth From IVF - ET Recruiting
Maternal Grandmothers in the Born in Guangzhou Cohort Study Recruiting
Guangzhou Preterm and Term Birth Cohort Study Active, not recruiting
IVF Offspring Born in Guangzhou Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03668327 on ClinicalTrials.gov ↗ ← All trials in China